Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open-Label, Randomized Phase II Study to Investigate the Efficacy and Safety of Pemetrexed-Cisplatin Plus Bevacizumab or Concurrent Thoracic Radiation Therapy as Induction Therapy Followed by Surgery in Stage IIIA (N2) Nonsquamous Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Multicenter, Open-Label, Randomized Phase II Study to Investigate the Efficacy and Safety of Pemetrexed-Cisplatin Plus Bevacizumab or Concurrent Thoracic Radiation Therapy as Induction Therapy Followed by Surgery in Stage IIIA (N2) Nonsquamous Non-Small Cell Lung Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms PIT-1

Most Recent Events

  • 04 Jun 2024 Results assessing exploratory analyses of survival, approximately 5 years after the last patient was randomly assigned presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 22 Jun 2020 New trial record
  • 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top